2017 Press Releases

August 15, 2017FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
August 14, 2017FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock
August 07, 2017FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
August 07, 2017FibroGen Reports Second Quarter 2017 Financial Results
July 31, 2017FibroGen to Report Second Quarter Financial Results on Monday, August 7, 2017
June 21, 2017FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
June 13, 2017FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
June 05, 2017European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology
May 09, 2017FibroGen Reports First Quarter 2017 Financial Results
May 03, 2017FibroGen to Report First Quarter Financial Results on May 9, 2017
April 06, 2017FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
March 31, 2017FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
March 30, 2017Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease
March 01, 2017FibroGen Reports Fiscal 2016 Financial Results
February 22, 2017FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017
February 03, 2017FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
January 30, 2017FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
January 20, 2017Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium